Ganoderma lucidum Polysaccharide Peptide Reduce Inflammation and Oxidative Stress in Patient with Atrial Fibrillation

Authors: Ardian Rizal, Ferry Sandra, Muhamad Rizki Fadlan, Djanggan Sargowo

Journal: Indonesian Biomedical Journal

Study Design:

• Intervention: 250 mg of Ganoderma lucidum polysaccharide peptide (GLPP) three times daily or placebo
• Participants: 38 subjects with paroxysmal atrial fibrillation (AF)
• Duration: 90 days
• Outcome Measures:
  • Anti-inflammatory and antioxidant markers (malondialdehyde, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-1b, interleukin-6)
  • Electrocardiography (P-wave dispersion, P-max)
  • Health-related quality of life (SF-36 questionnaire)

Summary: This study looked at the effects of Ganoderma lucidum polysaccharide peptide (GLPP) on people with a type of irregular heartbeat called atrial fibrillation (AF). The study found that taking GLPP for 90 days significantly reduced inflammation and oxidative stress (harmful molecules in the body) in these patients. It also improved the electrical signals in their hearts and their overall quality of life, including less fatigue and pain. These results suggest that GLPP could be a helpful addition to the treatment of AF.